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The 4 allele of apolipoprotein E (APOE) and traumatic brain injury
(TBI) are both risk factors for the development of Alzheimer’s
disease (AD). These factors may act synergistically, in that
APOE4 individuals are more likely to develop dementia after TBI.
Because the mechanism underlying these effects is unclear, we
questioned whether APOE4 and TBI interact either through effects
on amyloid- (A) or by enhancing cell death/tissue injury. We
assessed the effects of TBI in PDAPP mice (transgenic mice that
develop AD-like pathology) expressing human APOE3 (PDAPP:
E3), human APOE4 (PDAPP:E4), or no APOE (PDAPP:E/).
Mice were subjected to a unilateral cortical impact injury at 9–10
months of age and allowed to survive for 3 months. A load,
hippocampal/cortical volumes, and hippocampal CA3 cell loss
were quantified using stereological methods. All of the groups
contained mice with A-immunoreactive deposits (56% PDAPP:
E4, 20% PDAPP:E3, 75% PDAPP:E/), but thioflavine-S-
positive A (amyloid) was present only in the molecular layer of the
dentate gyrus in the PDAPP:E4 mice (44%). In contrast, our
previous studies showed that in the absence of TBI, PDAPP:E3
and PDAPP:E4 mice have little to no A deposition at this age.
After TBI, all of the A deposits present in PDAPP:E3 and PDAPP:
E/ mice were diffuse plaques. In contrast to the effect of
APOE4 on amyloid, PDAPP:E3, PDAPP:E4, and PDAPP:E/
mice did not differ in the amount of brain tissue or cell loss. These
data support the hypothesis that APOE4 influences the neurode-
generative cascade after TBI via an effect on A.
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The 4 allele of apolipoprotein E (APOE) and traumatic brain
injury (TBI) are both risk factors for the development of Alzhei-
mer’s disease (AD). It was first found that APOE4 was a risk
factor for AD in 1993 (Strittmatter et al., 1993), and numerous
studies have confirmed this association. Several studies have
found that individuals who sustained moderate to severe head
injury are more likely to develop dementia and AD (Mayeux et
al., 1993, 1995; Plassman et al., 2000). These risk factors appear to
act synergistically, in that individuals who are APOE4 are even
more likely to develop dementia if they sustain TBI at some time
in their life. For example, APOE4 individuals were 10 times
more likely to develop AD after TBI than those who were
APOE4, whereas APOE4 in the absence of injury was associated
with only twice the risk (Mayeux et al., 1995; Tang et al., 1996).
Although the mechanisms underlying these effects are unclear,
some evidence suggests that both APOE4 and TBI may influence
the risk of AD via interactions with the amyloid- (A) peptide.
For example, A deposition can be found in30% of people who
die shortly after TBI (Roberts et al., 1991, 1994); a significant
percentage of these patients are APOE4 (Nicoll et al., 1995,
1996). In addition, analysis of CSF from TBI patients revealed
elevated levels of A1–42 for up to a week after TBI, in com-
parison with both controls and AD patients (Raby et al., 1998;
Emmerling et al., 2000). In an evaluation of the effect of APOE3,
APOE4, or APOE/ in transgenic (TG) mice after TBI, greater
mortality was observed in APOE4 mice, whereas APOE3 mice
exhibited better neurological function between 3 and 11 d after
TBI (Sabo et al., 2000). Although APOE3 mice had less tissue
loss after TBI than APOE/ or wild-type mice, there was
no significant difference in tissue loss comparing APOE3
with APOE4 mice. The mice studied did not express human
amyloid precursor protein, so A deposition did not occur (Sabo
et al., 2000).
Because the mechanism by which the APOE genotype and TBI
interact to influence dementia remains unresolved, we questioned
whether APOE4 and TBI interact through effects on A, en-
hancement of cell death or tissue injury, or both. We used a well
characterized model of TBI (Smith et al., 1995) and assessed the
histological outcome in PDAPP mice (a TG mouse that develops
AD-like pathology) that either lack apoE or express human
APOE3 or APOE4.
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MATERIALS AND METHODS
PDAPP mice expressing amyloid precursor protein (APP) with a muta-
tion that causes familial AD (APP V717F) (Games et al., 1995) but lacks
the mouse APOE gene (PDAPP/, APOE/) (Bales et al., 1997)
were bred with mice that express human APOE under control of the glial
fibrillary acidic protein (GFAP) promoter (GFAP-APOE3 and GFAP-
APOE4 ) (Sun et al., 1998). The GFAP-APOE3 and GFAP-APOE4 mice
were all on a C57BL/6 mouse APOE/ background. The breeding
produced three types of TG mice (Holtzman et al., 2000): PDAPP/,
APOE/ (PDAPP:E/), PDAPP/, APOE3/ (PDAPP:E3),
and PDAPP/, APOE4/ (PDAPP:E4). Human APOE3 and
APOE4 TG mouse lines used in this experiment were matched for
APOE levels (Sun et al., 1998). The mice were subjected to a controlled
cortical impact injury (left hemisphere) (Smith et al., 1995) at 9–10
months of age, while under pentobarbital (65 mg/kg) anesthesia. This
injury results in underlying cortical damage with shrinkage of the hip-
pocampus and CA3 cell loss. Mortality rates immediately after TBI were
similar in all groups (25%), resulting in sample sizes of n  4 PDAPP:
E/, n  10 PDAPP:E3, and n  9 PDAPP:E4. At 12–13 months (3
months after injury), all mice were killed; their brains were removed,
fixed, frozen, and sliced into 50 m coronal sections from the genu of the
corpus callosum through the caudal extent of the hippocampus (Holtz-
man et al., 2000). Three sets of sections, each containing every sixth slice,
were collected from each brain. The sections were then mounted and
stained with pan anti-A antibody (Biosource, Camarillo, CA), cresyl
violet, or 4,6-diamidino-2-phenylindole (DAPI). Animals with A-
immunoreactive (IR) deposits were further analyzed using the Cavalieri
point-counting method with stereological software (Stereo Investigator;
MicroBrightField Inc., Colchester, VT) to quantify the area covered by
A-IR deposition (A load) as described previously (Holtzman et al.,
2000).
To obtain volume estimates of the hippocampus and cortex, cresyl
violet-stained sections were analyzed. Hippocampal measurements were
taken from every sixth section through the entire structure; cortical
measurements were taken from the first three anterior sections contain-
ing hippocampal tissue. The cortical region of interest was defined as
cortical tissue dorsal to the superior extent of the thalamus. The volumes
of the hippocampus and defined cortical region were determined using
the Stereo Investigator software. The percentage of hippocampal and
cortical tissue lost (ipsilateral vs contralateral to injury) was calculated
for each group.
In most animals, the inferior blade of the CA3 hippocampal field
exhibited a focal lesion ipsilateral to the injury, also noted in rodent
models of TBI (Nakagawa et al., 1999). CA3 neuronal counts were
obtained using DAPI-stained sections through the entire extent of the
hippocampus. A randomly selected subset of brains was analyzed (n  4
PDAPP:E/; n  5 PDAPP:E3; n  5 PDAPP:E4), and measurements
were taken from all sections that contained CA3 neurons. In each section,
the inferior blade of CA3 was traced using the computer. Estimates of
neuronal numbers were obtained with the optical fractionator technique
using Stereo Investigator software. The area was traced with a 4 lens,
and neurons were counted throughout the traced area using systematic
random sampling with a 100 lens.
The data were analyzed using Statistica 6.0 (Statsoft Inc., Tulsa, OK),
and  levels of p  0.05 were set for significance. The frequency of A
deposition was analyzed using  2 analysis. The percentage of the hip-
pocampus covered by A-IR was analyzed with a two-way ANOVA that
included one between-subjects factor (genotype: PDAPP:E3 vs
PDAPP:E4 vs PDAPP:E/) and one within-subjects factor (hemi-
sphere: ipsilateral vs contralateral to impact). Cortical and hippocampal
volume estimate data were analyzed with two-way ANOVAs that in-
cluded one between-subjects factor (genotype: PDAPP:E3 vs PDAPP:E4
vs PDAPP:E/) and one within-subjects factor (hemisphere: ipsilateral
vs contralateral to impact). CA3 neuronal counts were analyzed with a
two-way ANOVA that included one between-subjects factor (genotype:
PDAPP:E3 vs PDAPP:E4 vs PDAPP:E/) and one within-subjects
factor (hemisphere: ipsilateral vs contralateral to impact).
RESULTS
A analysis
Frequency and pattern of A deposition
We found previously that PDAPP mice expressing human
APOE3 or APOE4 do not develop A deposition until 15
months of age, when PDAPP:E4 mice in particular begin depos-
iting A and amyloid (Holtzman et al., 2000; Fagan et al., 2002).
In contrast, after TBI, we found that a high percentage of brain-
injured PDAPP:E4 mice had A deposition by 12–13 months of
age. In the PDAPP:E4 mice, 55.6% had A-IR deposits within
the hippocampus and 44% had thioflavine-S-positive A (fibrillar
amyloid) in the molecular layer (ML) of the dentate gyrus (Table
1). Among the PDAPP:E3 mice, only 20% had hippocampal
A-IR deposits, all of which were diffuse plaques. No PDAPP:E3
mice had fibrillar amyloid deposition. Significantly more
PDAPP:E4 mice had ML A-IR deposits compared with
PDAPP:E3 mice (2, p  0.02) (Fig. 1). This is notable because
A deposition in the ML of PDAPP mice coincides with the onset
of fibrillar A deposition and neuritic plaque formation (Holtz-
man et al., 2000; Fagan et al., 2002). Thus, only the PDAPP:E4
mice developed neuritic plaque formation after TBI at this age.
Assessment of A40 and A42 immunostaining of PDAPP:E3 and
PDAPP:E4 mice revealed the same pattern of staining as that
seen with the pan-A antibody (data not shown). Qualitatively,
the same differences between PDAPP:E3 and PDAPP:E4 mice
were noted with these antibodies. As in previous studies with
PDAPP and other human APP TG mice, neurofibrillary tangles
were not seen. Because PDAPP:E3 and PDAPP:E4 mice have
little to no A deposits at 12–13 months of age in the absence of
TBI (Holtzman et al., 2000; Fagan et al., 2002), TBI appears to
accelerate A deposition in the form of amyloid in the presence
of human APOE4 to a greater extent than APOE3. Consistent
with previous reports (Holtzman et al., 2000; Fagan et al., 2002),
three of the four PDAPP:E/ mice had hippocampal diffuse
A-IR deposits at 12 months of age; however, none were fibrillar.
Table 1. Histological analysis after TBI
PDAPP:E3 PDAPP:E4 PDAPP:E/ p  0.05
Sample size 10 9 4
Percentage of cortical loss 24.9 21.4 21.9 No
Percentage of hippocampal loss 9.2 9.3 8.5 No
Percentage of CA3 inferior blade neuron loss 35.7 30.0 26.6 No
Percentage of group with A-IR deposits 20 55.6 75 No
Percentage of group with molecular layer A-IR deposits 0 44.4 0 Yes
Contralateral to TBI: hippocampal A load (%) 0.1 0.9 13.8 Yes
Ipsilateral to TBI: hippocampal A load (%) 0.1 2.3 10.3 Yes
Contralateral to TBI: % of total A in molecular layer 0 28.1 0 Yes
Ipsilateral to TBI: % of total A in molecular layer 0 29.8 0 Yes
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Hippocampal A load
Analysis of all three groups revealed no significant difference
between the two hemispheres in the amount of A immunore-
activity. There was a significant main effect of genotype in that,
consistent with previous reports (Holtzman et al., 2000; Fagan et
al., 2002), PDAPP:E/ mice had a significantly greater A load
than PDAPP:E3 or PDAPP:E4 mice ( p  0.0001). However, the
A deposits present in PDAPP:E/ mice consisted of only
thioflavine-S-negative, diffuse A (i.e., nonfibrillar, nonamyloid
deposits). The amount of diffuse A in PDAPP:E/ mice after
TBI was not clearly increased compared with PDAPP:E/mice
in the absence of TBI (Holtzman et al., 2000; Fagan et al., 2002).
A separate PDAPP:E3 versus PDAPP:E4 analysis revealed a
significant main effect of genotype (PDAPP:E4  PDAPP:E3;
p  0.05) but no significant hemisphere effect. Approximately
35% of the hippocampal A load in PDAPP:E4 mice was con-
tained within the ML, whereas no PDAPP:E3 or PDAPP:E/
mice had ML deposition. Analysis of the percentage of A
deposition within the ML of the dentate gyrus revealed a signif-
icant main effect of genotype (PDAPP:E4  PDAPP:E3 and
PDAPP:E/; p  0.006) (Fig. 1).
Cortical and hippocampal volume estimates
Cortex
After TBI, the cortical volume ipsilateral to impact was signifi-
cantly less than the contralateral, nonimpacted hemisphere for all
groups ( p  0.0001) (Fig. 2). A main effect of genotype revealed
that PDAPP:E4 mice had slightly but significantly more cortical
tissue bilaterally than PDAPP:E3 or PDAPP:E/ mice, which
did not differ ( p  0.001). The hemisphere–genotype interaction
was not significant. The percentage of tissue loss in the cortex
ipsilateral versus contralateral to injury revealed no significant
genotype differences.
Hippocampus
After TBI, the hippocampus ipsilateral to impact was significantly
smaller than the contralateral hippocampus for all groups ( p 
0.008) (Fig. 2). A main effect of the genotype revealed that
PDAPP:E3 mice had slightly but significantly less overall hip-
pocampal tissue bilaterally than PDAPP:E4 or PDAPP:E/
mice, which did not differ ( p  0.001). The hemisphere–geno-
type interaction was not significant. The percentage of tissue loss
in the hippocampus ipsilateral versus contralateral to injury re-
vealed no significant genotype differences.
Neuronal counts (CA3 inferior blade)
After TBI, the inferior blade of CA3 ipsilateral to injury had
significantly fewer neurons (35% less) than the uninjured hemi-
sphere for all groups ( p  0.0005) (Fig. 3). There were no
significant genotype main effects or interactions. The percentage
of CA3 cell loss revealed no significant genotype differences.
Figure 1. A, Almost one-third of the total hippocampal A load was
contained in the ML of the dentate gyrus in PDAPP:E4 mice. Localiza-
tion of A deposition in the ML is associated with the formation of
fibrillar amyloid. In contrast, no ML A-IR deposits were found in
PDAPP:E3 or PDAPP:E/ mice 3 months after TBI. B, Photomicro-
graphs show A staining in the hippocampus (arrowheads delineate the
borders of the ML).
Figure 2. A, No group differences were found for percentage of area loss
in either the cortex or the hippocampus. B, Photomicrograph shows a
cresyl violet-stained brain section with atrophy of the cortex and hip-
pocampus in the injured hemisphere 3 months after TBI.
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DISCUSSION
Our previous work (Holtzman et al., 2000; Fagan et al., 2002)
demonstrated that A deposition in PDAPP mice that express
human APOE normally does not begin until 15 months of age,
6 months later than in animals expressing murine apoE. The
appearance of A-IR deposits by 12–13 months in the current
study suggests that TBI accelerated the A deposition process in
the presence of human APOE4. Furthermore, only PDAPP:E4
mice had significant A-IR deposits in the ML of the dentate
gyrus within 3 months of TBI. These ML deposits are associated
with thioflavine-S-positive staining, indicating the conversion of
soluble A to a -sheet conformation and neuritic plaque forma-
tion. As in our previous studies, PDAPP:E/ mice had higher
levels of A deposition than PDAPP:E3 or PDAPP:E4 mice, yet
none of these deposits consisted of true amyloid. Thus, although
the presence of APOE facilitates A fibril formation, human
APOE is likely also to play a role in A clearance. Our results
suggest that TBI and APOE4 (compared with APOE3) interact to
result in greater and earlier amyloid deposition. Overall, these
data suggest that the association with APOE4 and higher risk for
cognitive impairment and AD after TBI may in part be attribut-
able to APOE–A interactions.
Human studies have shown that both short- and long-term recov-
ery from TBI seem to be influenced by APOE. APOE4 individuals
scored significantly worse on neuropsychological tests 3 weeks after
mild to moderate TBI than APOE4 individuals (Liberman et al.,
2002), and APOE4 was predictive of longer periods of unconscious-
ness and worse clinical outcome after TBI (Friedman et al., 1999).
Furthermore, APOE4 individuals were twice as likely as APOE4
individuals to be dead, comatose, or severely disabled 6 months after
TBI (Teasdale et al., 1997). In addition to the poor general clinical
outcome associated with APOE4, memory performance within 6
months of head injury was worse in APOE4 patients compared
with APOE4 patients (Crawford et al., 2002), whereas APOE4 led
to worse motor function after TBI (Lichtman et al., 2000). Mild,
repetitive head injury also appears to interact with APOE. APOE4
professional boxers had significantly worse neurological scores on a
test of chronic brain injury that encompassed cognitive, motor, and
behavioral domains than boxers who were APOE4 (Jordan et al.,
1997). Similarly, older APOE4 professional football players scored
lower on cognitive tests than APOE4 players (Kutner et al., 2000).
Clinical and experimental TBI is also associated with acceler-
ated A deposition (Roberts et al., 1991), with an even greater
effect observed in APOE4 individuals on both parenchymal and
vascular A deposits (Nicoll et al., 1995, 1996; Macfarlane et al.,
1999; Leclercq et al., 2002). A deposition is also accelerated
after seizure-induced neurodegeneration, even in young
APOE4 subjects (Gouras et al., 1997). In addition to human
studies, the effects of TBI on A and AD pathology have also
been studied using TG mouse models of AD. Smith et al. (1998)
reported that TBI in PDAPP mice resulted in an 84% loss of CA3
neurons compared with only a 36% loss in non-TG mice. Naka-
gawa et al. (1999, 2000) have reported that TBI in both young and
old PDAPP mice induces atrophy and reduces A deposition in
the ipsilateral versus contralateral hippocampus. A deposition
after repetitive brain injury using different APP TG mice
(Tg2576) and milder cortical impact has also been reported (Uryu
et al., 2002). Our study extends these findings and demonstrates
the amyloid-promoting effects of human APOE4.
How TBI results in an isoform-dependent increase in amyloid
deposition is not clear. Both in vitro and in vivo studies demon-
strate that APOE can interact with A and influences the prob-
ability of whether A will aggregate in a -sheet conformation,
resulting in neuritic toxicity (for review, see Wisniewski et al.,
1997; Holtzman, 2001). The level of apoE plays a significant role
in this effect, because mouse apoE regulates A deposition in a
gene dose-dependent manner in vivo (Bales et al., 1997). The
effects of TBI on APOE–A interactions may be secondary to an
increase in APOE levels after TBI as well as alterations in
APOE-dependent A clearance. An increase in APOE levels has
been noted after multiple types of brain injury coincident with
glial activation (Teter, 2000). In addition to neuronal degenera-
tion, there is cellular reorganization with increased gliosis and
alterations in the vasculature. APOE can potentially interact with
different apoE receptors as well as the extracellular matrix. Be-
cause both of these factors change in regions of injury, APOE-
mediated A clearance may be reduced after TBI, thereby favor-
ing amyloid deposition. It is interesting that amyloid deposits
were increased not unilaterally but bilaterally after TBI in the
presence of APOE4. This suggests that mechanisms such as
changes in APOE expression and alterations in APOE-dependent
clearance are likely to occur bilaterally in this model of TBI.
The current study, in which the only known difference between
the groups of PDAPP mice was the presence or absence of human
APOE isoforms, provides evidence that isoform-specific
APOE–A interactions contribute to the premature development
of AD pathology. Although the promotion of amyloid deposition
per se is unlikely to lead to accelerated dementia, the neuritic
dystrophy associated with amyloid as well as other events coinci-
dent with or downstream of amyloid formation in humans are
likely to contribute to cognitive dysfunction. These processes
include A oligomer formation, tangle formation, cell loss, and
Figure 3. A, No group differences were found for neuronal loss within
the inferior blade of CA3. B, Photomicrograph shows a DAPI-stained
brain section revealing atrophy of the CA3 region (arrowheads delineate
the borders of the CA3 inferior blade) 3 months after TBI.
10086 J. Neurosci., December 1, 2002, 22(23):10083–10087 Hartman et al. • APOE4 and TBI
synaptic loss. Some in vivo studies have found that apoE influ-
ences aspects of brain function and plasticity after different forms
of injury (Fagan et al., 1998; Sheng et al., 1998; Stone et al., 1998;
Buttini et al., 1999; Genis et al., 2000; Sabo et al., 2000), including
TBI (Chen et al., 1997), and it is possible that APOE influences
the outcome after different forms of brain injury via more than
one mechanism. Our data suggest that understanding the mech-
anism(s) by which TBI promotes APOE isoform-dependent amy-
loid deposition will lead to important insights into how acceler-
ated A-related AD-like changes occur and potential ways to
prevent it.
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